SG11201909840TA - Treatment of epithelial cysts by intracystic injection of antineoplastic particles - Google Patents
Treatment of epithelial cysts by intracystic injection of antineoplastic particlesInfo
- Publication number
- SG11201909840TA SG11201909840TA SG11201909840TA SG11201909840TA SG 11201909840T A SG11201909840T A SG 11201909840TA SG 11201909840T A SG11201909840T A SG 11201909840TA SG 11201909840T A SG11201909840T A SG 11201909840TA
- Authority
- SG
- Singapore
- Prior art keywords
- crititech
- lawrence
- road
- international
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
- A61B8/0833—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
- A61B8/0841—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures for locating instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 December 2018 (13.12.2018) WIP0 I PCT omit VIII °nolo Homolomoimoommom (10) International Publication Number WO 2018/227037 Al (51) International Patent Classification: A61P 35/00 (2006.01) A61K 31/337 (2006.01) A61K 9/00 (2006.01) A61P 1/18 (2006.01) A61K 9/19 (2006.01) (21) International Application Number: PCT/US2018/036587 (22) International Filing Date: 08 June 2018 (08.06.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/517,711 09 June 2017 (09.06.2017) US (71) Applicant: CRITITECH, INC. [US/US]; 1849 E. 1450 Road, Lawrence, KS 66044 (US). (72) Inventors: DIZEREGA, Gere; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). BALTEZOR, Michael; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). DECEDUE, Charles; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). CAMP- BELL, Sam; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). MCCLOREY, Matthew; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). IACOBUCCI, Marc; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). MAULHARDT, Holly; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). (74) Agent: HARPER, David S.; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chicago, IL 60606 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (84) Designated States 11 N O N (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 00 (54) Title: TREATMENT OF EPITHELIAL CYSTS BY INTRACYSTIC INJECTION OF ANTINEOPLASTIC PARTICLES 0 (57) : Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection \" of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762517711P | 2017-06-09 | 2017-06-09 | |
PCT/US2018/036587 WO2018227037A1 (en) | 2017-06-09 | 2018-06-08 | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909840TA true SG11201909840TA (en) | 2019-11-28 |
Family
ID=62779068
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909840T SG11201909840TA (en) | 2017-06-09 | 2018-06-08 | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
SG10201913649TA SG10201913649TA (en) | 2017-06-09 | 2018-06-08 | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913649TA SG10201913649TA (en) | 2017-06-09 | 2018-06-08 | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
Country Status (11)
Country | Link |
---|---|
US (4) | US20190254957A1 (en) |
EP (1) | EP3615145B1 (en) |
JP (1) | JP2020523285A (en) |
KR (1) | KR20200014279A (en) |
CN (1) | CN110730679A (en) |
AU (1) | AU2018279634A1 (en) |
BR (1) | BR112019023948A2 (en) |
CA (1) | CA3063420A1 (en) |
RU (1) | RU2019134145A (en) |
SG (2) | SG11201909840TA (en) |
WO (1) | WO2018227037A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6921759B2 (en) | 2015-06-04 | 2021-08-18 | クリティテック・インコーポレイテッド | Collection device and usage |
AU2017246316B2 (en) | 2016-04-04 | 2022-09-29 | Crititech, Inc. | Methods for solid tumor treatment |
SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
CA3063436A1 (en) | 2017-06-14 | 2018-12-20 | Crititech, Inc. | Methods for treating lung disorders |
CA3076919A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
KR102526793B1 (en) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | Method for preparing albumin bound taxane nanoparticles with improved particle size distribution maintenance stability |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
US5874029A (en) | 1996-10-09 | 1999-02-23 | The University Of Kansas | Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
EP0954283B1 (en) | 1996-12-30 | 2007-03-21 | Battelle Memorial Institute | Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation |
CN100462066C (en) | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | Novel formulations of pharmacological agents, method for preparation thereof and method for use thereof |
KR101180181B1 (en) * | 1997-06-27 | 2012-09-05 | 아브락시스 바이오사이언스, 엘엘씨 | Nanoparticles and Method for the Preparation Thereof |
US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
JP3418751B2 (en) | 1998-01-22 | 2003-06-23 | 参天製薬株式会社 | Fluorometholone suspension ophthalmic solution |
IL131217A0 (en) | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
US6221153B1 (en) | 1998-06-09 | 2001-04-24 | Trevor Percival Castor | Method for producing large crystals of complex molecules |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6113795A (en) | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
WO2000030660A2 (en) | 1998-11-25 | 2000-06-02 | Universitätsklinikum Freiburg | Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
US6537585B1 (en) | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
US7217735B1 (en) | 1999-04-09 | 2007-05-15 | Au Jessie L-S | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
CA2371836C (en) | 1999-05-27 | 2006-01-31 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
US6616849B1 (en) | 1999-08-25 | 2003-09-09 | Shimadzu Corporation | Method of and system for continuously processing liquid materials, and the product processed thereby |
AU1374601A (en) | 1999-11-12 | 2001-05-30 | Angiotech International Ag | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
US6620351B2 (en) | 2000-05-24 | 2003-09-16 | Auburn University | Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer |
US6562952B1 (en) | 2000-10-31 | 2003-05-13 | The University Of Kansas | Precipitation of proteins from organic solutions |
US20020081339A1 (en) | 2000-12-22 | 2002-06-27 | Philippe Menei | Treatment of inoperable tumors by stereotactic injection of microspheres |
US20020192280A1 (en) | 2001-05-01 | 2002-12-19 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents |
US7276190B2 (en) | 2001-07-02 | 2007-10-02 | Micro & Nano Materials Sagl | Process for the production of micro and/or nano particles |
US20030054042A1 (en) | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
US20030134810A1 (en) * | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
WO2003032906A2 (en) | 2001-10-15 | 2003-04-24 | Crititech, Inc. | Delivery of poorly soluble drugs |
US20030166509A1 (en) | 2001-11-20 | 2003-09-04 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery and methods of use thereof |
EP1480691A4 (en) | 2002-03-05 | 2007-11-28 | Univ State Cleveland | Agglomerated particles for aerosol drug delivery |
DE60309300T3 (en) | 2002-03-20 | 2011-02-24 | Elan Pharma International Ltd. | NANOPARTICLE COMPOSITIONS OF ANGIOGENIC INHIBITORS |
AU2003226567A1 (en) | 2002-04-25 | 2003-11-10 | Nektar Therapeutics Uk Ltd | Particulate materials |
JP2005529127A (en) | 2002-04-26 | 2005-09-29 | テバ ファーマシューティカル インダストリーズ リミティド | Microparticle pharmaceutical composition for intratumoral delivery |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
CN1255394C (en) | 2002-06-24 | 2006-05-10 | 成都思摩纳米技术有限公司 | Process for the manufacture of pacilitaxel nano granule |
KR100573289B1 (en) | 2002-07-20 | 2006-04-24 | 대화제약 주식회사 | Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof |
WO2004098570A1 (en) | 2002-10-30 | 2004-11-18 | Spherics, Inc. | Nanoparticulate bioactive agents |
KR100508518B1 (en) | 2002-11-13 | 2005-08-17 | 한미약품 주식회사 | Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby |
TR200502189T1 (en) | 2002-12-09 | 2007-01-22 | American Bioscience, Inc. | Compositions and methods for the transfer of pharmacologically active substances. |
US7455797B2 (en) | 2003-02-28 | 2008-11-25 | Ferro Corporation | Method and apparatus for producing particles using supercritical fluid |
CA2520475C (en) | 2003-04-03 | 2012-10-09 | Jessie L.-S. Au | Tumor-targeting drug-loaded particles |
US20060147535A1 (en) | 2003-04-16 | 2006-07-06 | Poongunran Muthukumaran | Methods for and compositions of anticancer medicaments |
US20050059613A1 (en) | 2003-07-08 | 2005-03-17 | Bahram Memarzadeh | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
US8021831B2 (en) | 2003-08-25 | 2011-09-20 | Board Of Regents, The University Of Texas System | Taxane chemosensitivity prediction test |
JP2007001865A (en) | 2003-09-16 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | Fine particle enclosing fat-soluble medicine, method for producing the same and preparation containing the same |
CA2542217C (en) | 2003-10-15 | 2018-03-27 | Medigene Ag | Method of administering cationic liposomes comprising an active drug |
WO2005042219A1 (en) | 2003-10-24 | 2005-05-12 | Ferro Corporation | Method of forming particles |
CA2544627A1 (en) | 2003-11-05 | 2005-05-19 | Elan Pharma International Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
GB0402963D0 (en) | 2004-02-11 | 2004-03-17 | Univ Nottingham | Counter current mixing device for two different fluids |
US8043631B2 (en) | 2004-04-02 | 2011-10-25 | Au Jessie L S | Tumor targeting drug-loaded particles |
EP1818093B1 (en) | 2004-10-29 | 2014-03-12 | Nara Machinery Co., Ltd. | Method of granulating fine particles |
JP2008523151A (en) | 2004-12-14 | 2008-07-03 | トランセイブ, インク. | Lipid particles containing physiologically active substances, methods for their preparation and use |
ES2265262B1 (en) | 2005-01-31 | 2008-03-01 | Activery Biotech, S.L.(Titular Al 50%) | PROCEDURE FOR OBTAINING MICRO- AND NANODISPERSE SYSTEMS. |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
KR20080003322A (en) | 2005-02-24 | 2008-01-07 | 엘란 파마 인터내셔널 리미티드 | Nanoparticulate formulations of docetaxel and analogues thereof |
US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
CN101160116B (en) | 2005-03-31 | 2011-12-07 | 利德斯公司 | Method for treating prostate diseases based on local delivery of active substances |
CN1923189A (en) | 2005-08-30 | 2007-03-07 | 孔庆忠 | Taxine kind anti-cancer slow release injection |
CN101291658B (en) * | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
WO2007065446A2 (en) | 2005-12-11 | 2007-06-14 | Scf Technologies A/S | Production of nanosized materials |
US8906392B2 (en) | 2005-12-16 | 2014-12-09 | University Of Kansas | Nanocluster compositions and methods |
AR054215A1 (en) | 2006-01-20 | 2007-06-13 | Eriochem Sa | A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT |
CN101336899A (en) | 2006-01-25 | 2009-01-07 | 济南帅华医药科技有限公司 | Anticancer sustained-released injection containing taxane |
DE602007005231D1 (en) | 2006-03-14 | 2010-04-22 | Lidds Ab | BIORESORBABLE COMPOSITION WITH CONTROLLED RELEASE |
US7744923B2 (en) | 2006-10-11 | 2010-06-29 | Crititech, Inc. | Method for precipitation of small medicament particles into use containers |
TWI405590B (en) | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | Method of producing pulverized organic compound particle |
WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
WO2009006590A2 (en) | 2007-07-04 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Docetaxel process and polymorphs |
CN101129338A (en) | 2007-08-27 | 2008-02-27 | 四川大学 | Minuteness anti-cancer medicine paclitaxel of novel technique supercritical fluid |
AU2009222230A1 (en) | 2008-03-06 | 2009-09-11 | Nitto Denko Corporation | Polymer paclitaxel conjugates and methods for treating cancer |
ES2467676T3 (en) | 2008-09-19 | 2014-06-12 | Activus Pharma Co., Ltd. | Powder of a combined organic compound for medical use, method for producing the same and suspension thereof |
EP3181123A1 (en) * | 2008-12-02 | 2017-06-21 | Biocompatibles Uk Ltd. | Pancreatic tumour treatment |
PT104693B (en) | 2009-07-27 | 2011-11-24 | Univ Lisboa | SEMI-SOLID LIPID NANOPARTICLES CONTAINING AN ANTINEOPLASTIC AGENT AND ITS PREPARATION PROCESS |
EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
CN101829061A (en) | 2010-05-14 | 2010-09-15 | 无锡纳生生物科技有限公司 | Taxol nanoparticle composition and preparation method thereof |
NZ708506A (en) | 2010-06-02 | 2016-08-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
CA2811869A1 (en) | 2010-09-21 | 2012-03-29 | Cristal Delivery B.V. | Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith |
JP2014504260A (en) | 2010-10-15 | 2014-02-20 | グラクソ グループ リミテッド | Aggregated nanoparticulate drug formulation, its manufacture and use |
WO2012096995A2 (en) | 2011-01-11 | 2012-07-19 | Boston Scientific Scimed, Inc. | Coated medical devices |
KR20140022904A (en) | 2011-04-20 | 2014-02-25 | 유니버시티 오브 시드니 | A method for the treatment of a solid tumour |
WO2013052158A2 (en) | 2011-04-26 | 2013-04-11 | William Marsh Rice University | Targeted nanovectors and their use for treatment of brain tumors |
EA201490047A1 (en) | 2011-06-17 | 2014-08-29 | Берг Ллк | INHALATION PHARMACEUTICAL COMPOSITIONS |
EP2723388B1 (en) | 2011-06-27 | 2021-04-14 | Cristal Delivery B.V. | Controlled release system |
FR2980683B1 (en) | 2011-09-30 | 2014-11-21 | Univ Paris Curie | DEVICE FOR GUIDING A MEDICAL INSTRUMENT INSERTED IN A NATURAL PATH OR AN ARTIFICIAL PATH OF A PATIENT |
CN102488682A (en) | 2011-11-22 | 2012-06-13 | 四川九章生物化工科技发展有限公司 | New application of chlorogenic acid in cancer resisting |
US10555911B2 (en) | 2012-05-04 | 2020-02-11 | Yale University | Highly penetrative nanocarriers for treatment of CNS disease |
TW201408304A (en) | 2012-08-31 | 2014-03-01 | Cathay General Hospital | A combined drug with anti-cancer drug and hormone to treat renal cell carcinoma and its method of fabrication |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
PL2961377T3 (en) | 2013-02-28 | 2020-11-02 | Pf Consumer Healthcare 1 Llc | Enhanced stability of novel liquid compositions |
US9925512B2 (en) | 2013-03-14 | 2018-03-27 | Crititech, Inc. | Equipment assembly for and method of processing particles |
US8778181B1 (en) | 2013-03-14 | 2014-07-15 | Crititech, Inc. | Equipment assembly for and method of processing particles |
WO2014155146A1 (en) | 2013-03-28 | 2014-10-02 | Bbs Nanotechnology Llc | Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it |
US9301926B2 (en) | 2013-04-10 | 2016-04-05 | Massachusetts Institute Of Technology | Local drug delivery devices and methods for treating cancer |
US10188738B2 (en) | 2013-10-16 | 2019-01-29 | Université Libre de Bruxelles | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract |
HUE047699T2 (en) | 2013-12-17 | 2020-05-28 | Hoffmann La Roche | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
KR20230076867A (en) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | Combination therapy with neoantigen vaccine |
WO2015103005A1 (en) * | 2014-01-03 | 2015-07-09 | Research Institute At Nationwide Children's Hospital | Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers |
TWI601542B (en) | 2014-04-18 | 2017-10-11 | 林信湧 | Inhalation-type pharmaceutical composition for lung cancer and preparation method thereof |
US20150342872A1 (en) | 2014-06-01 | 2015-12-03 | Crititech, Inc. | Use of Paclitaxel Particles |
US11033620B2 (en) | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
JP6921759B2 (en) | 2015-06-04 | 2021-08-18 | クリティテック・インコーポレイテッド | Collection device and usage |
AU2016323770A1 (en) | 2015-09-16 | 2018-03-29 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
AU2016326747A1 (en) * | 2015-09-25 | 2018-03-01 | Zy Therapeutics Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
DE202016006620U1 (en) | 2015-10-28 | 2017-04-12 | Qass Gmbh | Devices for observing a magnetic field of a material volume |
CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
AU2017246316B2 (en) | 2016-04-04 | 2022-09-29 | Crititech, Inc. | Methods for solid tumor treatment |
CN107281502B (en) | 2016-04-05 | 2021-05-04 | 上海市肿瘤研究所 | Composite developing temperature-sensitive gel suppository, preparation method and application thereof |
WO2017178585A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
KR102462041B1 (en) | 2016-09-01 | 2022-11-02 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Carrier for cancer treatment-PD-L1 binder composition |
WO2018170210A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes |
ES2955884T3 (en) | 2017-03-15 | 2023-12-07 | Dfb Soria Llc | Topical therapy for the treatment of skin malignancies with taxane nanoparticles |
WO2018170207A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes |
SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
CA3063436A1 (en) | 2017-06-14 | 2018-12-20 | Crititech, Inc. | Methods for treating lung disorders |
-
2018
- 2018-06-08 SG SG11201909840T patent/SG11201909840TA/en unknown
- 2018-06-08 JP JP2019563250A patent/JP2020523285A/en active Pending
- 2018-06-08 AU AU2018279634A patent/AU2018279634A1/en not_active Abandoned
- 2018-06-08 CA CA3063420A patent/CA3063420A1/en active Pending
- 2018-06-08 BR BR112019023948A patent/BR112019023948A2/en not_active Application Discontinuation
- 2018-06-08 SG SG10201913649TA patent/SG10201913649TA/en unknown
- 2018-06-08 CN CN201880036802.4A patent/CN110730679A/en active Pending
- 2018-06-08 KR KR1020197033608A patent/KR20200014279A/en unknown
- 2018-06-08 RU RU2019134145A patent/RU2019134145A/en not_active Application Discontinuation
- 2018-06-08 EP EP18735083.0A patent/EP3615145B1/en active Active
- 2018-06-08 WO PCT/US2018/036587 patent/WO2018227037A1/en unknown
-
2019
- 2019-04-12 US US16/382,446 patent/US20190254957A1/en not_active Abandoned
-
2021
- 2021-05-10 US US17/315,804 patent/US11523983B2/en active Active
-
2022
- 2022-10-12 US US18/046,002 patent/US11737972B2/en active Active
-
2023
- 2023-07-13 US US18/351,711 patent/US20230372234A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190254957A1 (en) | 2019-08-22 |
EP3615145A1 (en) | 2020-03-04 |
KR20200014279A (en) | 2020-02-10 |
CN110730679A (en) | 2020-01-24 |
US20210259959A1 (en) | 2021-08-26 |
AU2018279634A1 (en) | 2019-10-31 |
JP2020523285A (en) | 2020-08-06 |
US11737972B2 (en) | 2023-08-29 |
US11523983B2 (en) | 2022-12-13 |
US20230372234A1 (en) | 2023-11-23 |
EP3615145B1 (en) | 2024-05-15 |
CA3063420A1 (en) | 2018-12-13 |
RU2019134145A (en) | 2021-07-09 |
WO2018227037A1 (en) | 2018-12-13 |
BR112019023948A2 (en) | 2020-06-09 |
SG10201913649TA (en) | 2020-03-30 |
US20230111288A1 (en) | 2023-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909840TA (en) | Treatment of epithelial cysts by intracystic injection of antineoplastic particles | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201805229YA (en) | Means and methods for treating hbv | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201902567WA (en) | Expec glycoconjugate vaccine formulations | |
SG11201810940XA (en) | Methods of treating pancreatic cancer |